Search Results for "emtricitabine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for emtricitabine. Results 1 to 3 of 3 total matches.
Lenacapavir (Yeztugo) for HIV-1 Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • Jul 22, 2025 (Issue 5118)
emtricitabine/tenofovir disoproxil
fumarate and emtricitabine/tenofovir alafenamide.
▶ Adverse Effects: Most ...
The FDA has approved oral and injectable formulations
of the HIV-1 capsid inhibitor lenacapavir (Yeztugo –
Gilead) for pre-exposure prophylaxis (PrEP) to reduce
the risk of sexually acquired HIV-1 in at-risk adolescents
and adults. Lenacapavir is the first drug to be approved
for this indication that is given twice-yearly; other drugs
approved for this indication are given once daily or once
every 2 months. Lenacapavir was approved in 2022
as Sunlenca for use with other antiretroviral drugs to
treat multidrug-resistant HIV-1 infection (MDR-HIV) in
heavily treatment-experienced...
Med Lett Drugs Ther. 2025 Jul 22;67(5118):1-3 doi:10.58347/tml.2025.5118a | Show Introduction Hide Introduction
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
: emtricitabine/
tenofovir disoproxil fumarate (FTC/TDF; Truvada,
and generics), which can be used in any ...
The FDA has approved Apretude (ViiV Healthcare),
an IM extended-release (ER) formulation of the integrase
strand transfer inhibitor (INSTI) cabotegravir,
for use every 2 months to prevent sexually acquired
HIV-1 infection in at-risk adolescents and adults.
Apretude is the first ER formulation to be FDA-approved
for pre-exposure prophylaxis (PrEP) of
HIV-1 infection.
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate Increased tenofovir serum concentrations ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction